AZ’s Saphnelo scores US approval for systemic lupus erythematosus

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Saphnelo (anifrolumab) for the treatment of moderate to severe systemic lupus erythematosus (SLE).